Run 2026-06-04 · data as of 2026-06-04 · descriptive relative-strength snapshot, not a forecast
This is an AI-led uptrend taking a one-day breather, not a leadership handoff.
Since No. 25 (2026-06-03)AVGO: Buyable → Avoid (-12.6%)CRWD: Buyable → Extended (-3.8%)PANW: Buyable → Extended (-0.4%)CCJ: Buyable → Too early (-0.5%)AEM: Extended → Too early (+3.0%)RGTI: Too early → Avoid (+0.2%)IBM: Buyable → Extended (-1.3%)IREN: Basing → Extended (-5.5%)NVDA: Basing → BuyableCRSP: Basing → Buyable
Fundamentalsno grade changes — fundamentals held within all bands
Quotes & fundamentals: FMP, as of 2026-06-04
Important: This is general market commentary and research, not personalized investment advice or a recommendation to buy or sell any security. Relative strength is a descriptive, backward-looking signal, not a forecast. Markets carry risk and you can lose money; do your own research and consider your own circumstances. The author may hold positions in securities mentioned.
How we pick leaders — in 30 seconds
We rank market themes by relative strength, find the strongest names inside the leading themes, and verify every quote and return against live market data at publish time. Each name gets one call: Buyable (at a buy point) · Basing (watch for a breakout) · Wait (strong, no setup yet) · Extended (overbought, await a pullback) · Too early (unconfirmed bounce) · Avoid (downtrend). Relative strength is a descriptive, backward-looking signal — not a forecast.
5
Leading themes
4
Buyable ideas
TSM · ETN · ELV · GE
8
Fading / avoid
AI Semiconductors
Strongest theme
FolioMind · No. 26as of 2026-06-04
This is an AI-led uptrend taking a one-day breather, not a leadership handoff.
Buyable nowTSMETNELVGE
1Market regime
The tape made that clear on June 4. The Dow hit a record (51,561.93, +1.73%) and the Russell 2000 closed at a fresh high (2,935.33, +1.45%), so the day looked like a "Great Rotation." But the multi-week relative strength says otherwise.
AI semis are still the only theme leading on every horizon that matters. SMH is up roughly 57% over three months and sits about 2-3% from its all-time high.
The headline rotation winner, Financials, fails the test outright. XLF is up only 1.3% over three months and is the ONLY major sector still below its 200-day moving average.
That is a deep laggard catching a single-session mean-reversion bid, not new leadership. GS is the lone exception inside the group — a genuine capital-markets leader at a fresh 52-week high (3m +30.8% vs XLF +1.8%); judge it on its own relative strength, not the sector tag.
The genuine broadening is narrower than the headline. Small-caps and equal-weight are real and accelerating (IWM +11.6% 3m to a fresh high).
Healthcare is the cleanest early laggard-to-leader turn (XLV reclaimed its 200-day on a multi-week base, with LLY up 25% in three weeks). Defensives did NOT lead, so the move was risk-ON broadening, not a flight to safety.
Net: stay long the confirmed AI/semi/copper/data-center-buildout leadership even though it is extended, treat small-caps and healthcare as the credible early adds, and do not chase the financials or precious-metals reflex the tape does not support. Important: this is one verification snapshot, not a forecast.
Hard returns dominate the day's narrative wherever the two disagree.
Small-caps and equal-weight are real and accelerating (IWM +11.6% 3m to a fresh high).
◆Theme strength & rotation
Each theme’s leadership strength (0–100, from its leaders’ proximity to 52-wk highs, relative strength vs the proxy, and momentum), tracked across issues. ▲ strengthening · ▼ rolling over · ● holding · ✦ new. The number is the change vs the last issue this theme appeared. A theme that is rising but not yet at the top is where leadership may be emerging.
✓ Buyable at a buy point→ Basing watch for breakout⏸ Wait strong, no setup yet⚠ Extended overbought, await pullback⌛ Too early unconfirmed bounce✕ Avoid downtrend
Show
AI Semiconductors / Compute
extended-late●●●high● 81 +05 names▾
What’s driving it. Hyperscaler AI-compute capex is still ramping. The June 4 AVGO drop was a one-day de-risk of a crowded winner, not a theme break.
AVGO held its AI guide steady ($16B Q3) and its AI revenue still grew 143% YoY, while NVDA (+1.8%) and MRVL (+4.9%) rose the same session. Intra-group dispersion proves it was profit-taking, not a leadership failure.
Durability. Sustainable as a theme, but late-stage on price. The demand driver is multi-year and underwritten by named hyperscaler commitments.
The risk is not relative-strength failure, it is crowding and extension. So the theme leads but entries must be selective.
Quality (TSM) is buyable; momentum (MRVL) is a parabola you chase at your peril.
Leaders’ fundamental health. Bifurcated. The two best businesses (NVDA, TSM) are genuinely strong: NVDA runs 75% gross margins, 85% revenue growth, 63% ROIC, net cash, at a reasonable 33x P/E.
TSM is net cash, 66% gross margin, 32% ROE, ~20x earnings. But the two RS movers are weaker: MRVL is a 1.4% net margin, ~6% ROIC name at ~29x EV/sales, and AVGO is stretched at 68x P/E.
In aggregate the anchors are pristine; the momentum names are hollow.
Current leadersTSM · NVDA · MRVL · AVGO · DELL
− Removed leadersINTCstill strong droppedINTC at $111.78 is 15.8% off its $132.75 high but trades well above its 50DMA ($86.37) and 200DMA ($50.46) on a -0.8% day, so the turnaround leadership is intact and it was simply not re-picked, not weak.
Relative strength. Leading cleanly. At its 52-week high, well above both moving averages, and it rose +1.9% on AVGO's down day — true pick-and-shovel breadth.
Valuation. The highest-quality entry here: leading-edge logic plus CoWoS packaging gates the whole AI-compute chain, ~20x earnings, net cash, 32% ROE. Slightly trails the broad semis ETF on 3m/YTD, so it is a co-leader rather than the single strongest mover; binding tail risk is geopolitical concentration, not the business.
Relative strength. Lagging the theme on relative strength. It trails the semis ETF on every horizon (1m +11.3% vs +20%, 3m +19.3% vs +59%, YTD +16% vs +68%).
Valuation. Best fundamentals in the group and reasonably valued at 33x for 85% growth. The catch is it is not the RS leader the proposal claims; it is a lagging mega-cap anchor.
Relative strength. Leading by a wide margin, but vertically. It is up ~4x in three months and trades at ~2x its 50-day and ~3x its 200-day average.
Valuation. The price is a parabola detached from earnings: Q1 FY27 net income was just $34.5M on $2.4B revenue (EPS $0.04). A June 2 'next trillion-dollar company' headline drove the final blow-off leg.
Relative strength. Lagging the group right now. It is the only name down on the day (-12.6%), the only one below the SMH theme proxy on 1m, and the furthest from its 52-week high.
Valuation. Record AI revenue is real, but a 12.6% one-day drop on a software miss plus 68x earnings is not a 'dominant-leader' tape. 16-analyst avg target ~$504 sits ~20% above price; let it reclaim the 50-day before trusting it.
Relative strength. LEADING proxy SMH massively — YTD +230.2% vs SMH +68.1% (+162.1pp); 3m +186.9% vs SMH +57.3% (+129.6pp); 1m +99.2% vs SMH +23.8% (+75.3pp)
Valuation. Strong cash generation (~$15B FCFE, 11% FY-end FCF yield) and a low ~0.84x EV/sales reflect the thin-margin (20% GM) hardware model, but negative book equity from aggressive buybacks and a ~47x trailing P/E after a 235% YTD run leave little room for execution slips.
What’s driving it. Thermal management and power distribution are the physical bottleneck of AI datacenter buildout, underwritten by hyperscaler commitments (Meta ~6.6 GW by 2035). Capital stays in the build-out regardless of which power generator wins, which is why this layer held trend while CEG/VST/OKLO broke theirs.
Durability. Sustainable on the demand story but momentum has cooled near-term. VRT, the bellwether, is down 2% on the month and 15% off its high.
NVT presses new highs but on M&A-inflated growth. The structural buildout thesis is durable; the immediate setups are mostly extended, so this leads but offers only one clean entry (ETN).
Leaders’ fundamental health. Solid but mixed. ETN and VRT are the Strong ones: ETN at ~23x EV/EBITDA, 13% ROIC, 3.6% FCF yield, reasonable leverage; VRT at ~29x EV/EBITDA (NOT the 175x the original thesis hallucinated), 19% ROIC, 30% revenue growth.
NVT is Mixed — acquisition-built with only ~8% ROIC and 66% of assets in intangibles (leverage is fine at 1.8x, NOT the 5.8x originally claimed). PWR is Stretched — a 13% gross-margin contractor at 62x P/E.
In aggregate, healthy cash generation but valuations price the backlog as a given.
Relative strength. Strongest relative strength in the group. Up nearly 7% on the month and sitting just 2% under its 52-week high while the others have faded.
Valuation. Pressed against the high after a 60%+ YTD run, so entries here are chasing. Leverage is fine, but ROIC is only ~8% and most growth is acquired, not organic.
Relative strength. Leading on trend and the de-facto theme bellwether. But it has cooled near-term: down 2% over the past month and 15% off its high while NVT presses new highs.
Valuation. Pricey but not absurd. The proposed thesis's '~175x EV/EBITDA' is wrong; the real multiple is ~29x on FY25 (about 57x on Q1-annualized EBITDA).
Relative strength. Constructive but lower-octane. It is the steadiest name and sits 4% off its high, yet its YTD gain is a fraction of the group's high-flyers, so on pure relative strength it is the laggard of the four.
Valuation. The most reasonably priced and best-quality name here. The trade-off is that data-center is diluted by slower vehicle/aerospace/industrial end-markets, so it moves less than the pure-plays.
Relative strength. Leading on the long trend but the weakest right now. It tagged its 52-week high on May 6 and has since rolled over 9%, the worst one-month tape of the four.
Valuation. Contractor economics mean thin 13% gross / 3.6% net margins and a 62x P/E that prices the backlog as a given. The near-term tape is the warning: -5% on the month off a high, momentum is fading.
Relative strength. LEADING proxy XLU — YTD +26.7% vs XLU +1.7% (+25.0pp); 3m +23.1% vs XLU -7.1% (+30.2pp); 1m -3.8% vs XLU -5.3% (+1.5pp)
Valuation. Best-in-class fundamentals: 64% gross margin, 39% net margin, 28% ROE, $4.25B FCF and a debt-free, net-cash balance sheet. Quality is unimpeachable; the only caution is valuation, with EV/S ~24x and EV/EBITDA ~55x demanding sustained hyperscaler AI-networking demand.
Copper — AI/electrification structural leader
established-leading●●●high▲ 78 +133 names▾
What’s driving it. Structural demand from AI datacenters plus electrification. Copper futures ripped to a record above $13,000/ton, with demand projected to climb from 28M to 42M tons by 2040.
This is the opposite posture to gold, silver and uranium, which are all below their 50-day averages.
Durability. Sustainable. This is a multi-decade physical demand story, not a momentum trade.
FCX sits far above both its 50-day ($62.87) and 200-day ($53.02). The June 4 -1.3% day is profit-taking inside an intact uptrend.
The structural copper-supply-deficit narrative gives this more legs than the rest of the real-asset complex.
Leaders’ fundamental health. Note: copper leader fundamentals were not independently verified in this run, so this is a lighter-conviction read. Diversified large-cap miners like FCX and SCCO are generally cash-generative with reasonable balance sheets, but commodity producers carry cyclical earnings and are highly geared to the copper spot price.
Treat the leadership as price/RS-driven; size for commodity volatility.
Current leadersFCX · SCCO · TECK
− Removed leadersEROrs fadedERO at $30.76 sits 22.7% below its 52-wk high ($39.80) and, while still above its 50-DMA ($28.07) and 200-DMA ($25.37), it continues to lag the copper-theme proxy with relative strength that has faded versus the structural leaders.
Relative strength. LEADING its copper proxy COPX on every window: YTD +37.2% vs COPX +25.9%, 1m +25.4% vs +17.6%, 3m +5.7% vs +2.4%. As a large-cap US copper pure-play it is at the front of the move, sitting just 3.3% below its 52w high vs COPX 9.8% below.
Valuation. Copper-volume leverage is real but FY25 revenue was nearly flat and FCF is compressed by heavy growth capex, so at ~46x trailing earnings and ~12x EV/EBITDA the stock is pricing in a copper up-cycle rather than current cash generation.
Relative strength. MIXED vs copper proxy COPX: leads YTD (+35.2% vs +25.9%) but lags on 3m (-6.1% vs +2.4%) and sits deeper below its high (-12.4% vs COPX -9.8%). A high-quality but lower-beta name that led early and has cooled while the group consolidated.
Valuation. Best-in-class copper economics — ~57% gross margin, ~39% ROE and a near-unlevered balance sheet — but quality is fully priced at ~21x EV/EBITDA and ~12x sales, the richest valuation in the copper group.
Relative strength. LEADING its copper proxy COPX across all windows by a wide margin: YTD +40.5% vs +25.9%, 3m +21.2% vs +2.4%, 1m +18.5% vs +17.6%, and only 5.6% off its high vs COPX 9.8%. The strongest relative performer of the three copper names.
Valuation. Cheapest on asset value (P/B 1.3x, EV/EBITDA 8.6x) as it re-rates into a copper-growth story, but FY25 free cash flow is negative under elevated growth capex and returns (ROE 5.6%, ROIC 2.8%) are thin — the bull case is the copper pipeline, not current cash returns.
Cybersecurity
established-leading●●●high▲ 76 +84 names▾
What’s driving it. AI-security is becoming the category's growth vector. CRWD was named in both Anthropic's and OpenAI's cyber programs.
CRWD's -3.8% on June 4 came AFTER record Q1 net-new ARR ($256M, +32% YoY), record FCF ($468M), and a RAISED FY27 guide — a classic strong-print dip. It still sits +51% above its 200-day.
Durability. Sustainable. These are defensive-growth platforms that travel well through a leadership rotation.
Both CRWD and PANW held well above their moving averages through the broad risk-rotation day. Recurring ARR-based revenue and platform consolidation make this less regime-fragile than most AI-derivative themes.
Leaders’ fundamental health. Note: cyber leader fundamentals were not independently verified in this run. From the live data we do have, CRWD just printed record FCF ($468M) and raised guidance, which signals strong cash generation.
These are high-multiple SaaS-security names where the valuation, not the business, is the risk. Treat as descriptively healthy but priced for growth.
Relative strength. LEADING its cybersecurity proxy CIBR decisively: YTD +53.4% vs +27.0%, 3m +76.4% vs +40.2%, 1m +53.2% vs +30.0%. The clear group leader, roughly doubling the ETF's move on every window, though today's -3.8% print pulled it back to 8.5% under its high.
Valuation. Durable ~22% subscription growth, 75% gross margins, ~22% FCF margin and a net-cash balance sheet make the franchise high-quality, but GAAP earnings are negative and at ~37x EV/sales after a +76% three-month run the valuation leaves no margin for error.
Relative strength. LEADING its theme proxy CIBR (First Trust Nasdaq Cybersecurity ETF) decisively: PANW +71.1% over 3m and +51.6% YTD vs CIBR +37.9% / +27.0%, and +51.8% over 1m vs CIBR +27.9%. The dominant pure-play cyber large-cap driving the group.
Valuation. Platformization-driven double-digit growth, fat 73% gross margins, robust FCF and a net-cash balance sheet make the franchise high quality, but at ~20x EV/sales and ~97x trailing EV/EBITDA the multiple is rich and prices in years of compounding.
Relative strength. LEADING CIBR by a wide margin: FTNT +88.5% YTD and +77.3% over 3m vs CIBR +27.0% / +37.9%, and +66.4% over 1m vs CIBR +27.9%. The single strongest theme leader, printing fresh 52-week highs.
Valuation. Best-in-class profitability for a cyber name (81% gross margin, 30%+ operating margin, 33% FCF margin) with a net-cash sheet; the business quality is excellent but after nearly doubling YTD the ~16x EV/sales and ~44x EV/EBITDA leave little valuation cushion.
Relative strength. LAGGING CIBR badly: ZS -38.7% YTD and -16.5% over 3m while CIBR is +27.0% / +37.9%; it trades below its 50DMA ($143) and 200DMA ($220). A clear theme laggard while the rest of the group makes highs.
Valuation. Fastest top-line grower of the cyber cohort (+23%) with strong FCF and a fortress net-cash sheet, but still GAAP-unprofitable and the chart is broken (-60% from high); cheaper at ~8x EV/sales than peers, yet the price action says the market is repricing the growth deceleration.
GLP-1 / obesity & large-cap pharma
established-leading●●●high● 62 -45 names▾
What’s driving it. The GLP-1 catalyst is de-risked and commercial. LLY's oral GLP-1 orforglipron (Foundayo) was FDA-approved April 1 and is shipping via LillyDirect.
LLY is at a fresh 52-week high after a +25% three-week run that PREDATES the June 4 broadening, so the relative strength has a genuine multi-week base.
Durability. Sustainable on the franchise, but LLY is a momentum leader at an extreme valuation, not a cheap turn. The obesity TAM is structural and the oral-pill launch is real.
But LLY trades at ~15x sales and 47x earnings with sub-1% FCF yield, so any manufacturing or share-war stumble hits hardest. Durable theme, expensive entry.
Leaders’ fundamental health. Best operating quality in healthcare, stretched valuation. LLY runs 84% gross margin, 32% net margin, 78% ROE, 30% ROIC — elite economics — but at EV/S 15x and P/E 47x it is priced for perfection, and heavy oral-GLP-1 capex keeps FCF yield under 1%.
ABBV is the levered laggard here (net-debt/EBITDA 3.6x, negative book equity). In aggregate, world-class margins paired with little valuation cushion.
Current leadersLLY · NVO · VKTX · ABBV · WST
+ New leadersNVOreturningNVO bounced +4.17% to $43.75, holding above its 50DMA ($41.48) but still -46.3% below its 52-week high ($81.44) and under its 200DMA ($48.84), a tentative return of short-term strength within a deep downtrend.VKTXdisplaced incumbentVKTX at $29.78 (+1.53% day) enters as a GLP-1/obesity theme fill rather than a breakout — it trades 31% below its $43.15 52wk high and below both its 50-DMA ($32.34) and 200-DMA ($32.33), still basing not leading.
Relative strength. Leading, but as a momentum leader not a laggard turn. At a fresh 52wk high, far above its 50-DMA ($964) and 200-DMA ($943).
Carries the pharma half of the XLV breakout.
Valuation. Best operating quality in the group (32% net margin, 30% ROIC) but priced for perfection at ~15x sales and 47x earnings. Heavy capex on oral-GLP-1 capacity keeps FCF yield under 1%.
Any manufacturing or share-war stumble hits a richly-priced stock hardest.
Relative strength. MIXED vs theme proxy XLV (Health Care Select SPDR): NVO is LEADING over 3m (+12.0% vs XLV -1.2%) as it bounces off the lows and reclaims its 50DMA ($41.48), but still LAGGING YTD (-16.5% vs XLV -1.8%) and sits below its 200DMA ($48.84) after a brutal 12-month de-rate.
Valuation. Elite profitability (81% GM, 51% EBITDA margin, 53% ROE) at the cheapest multiple of any large-cap GLP-1/pharma growth name (~14x P/E, ~10x EV/EBITDA) after a 46% drawdown; the de-rate reflects slowing growth (+6%) and competitive/pipeline concerns, but the fundamentals remain firmly investment-grade.
Relative strength. LAGGING its theme proxy XBI badly: VKTX -15.3% YTD / -5.5% 3m / -4.9% 1m vs XBI +9.4% YTD / +7.7% 3m / -0.3% 1m — a ~25pp YTD shortfall. Trades below both 50DMA ($32.34) and 200DMA ($32.33) while the biotech complex grinds to new highs.
Valuation. No revenue and a widening ~$360M annual burn make conventional multiples meaningless; the ~$3.5B market cap is pure pipeline optionality (oral/SC obysity GLP-1 candidates) backed by a strong ~$640M net-cash balance sheet that funds trials but does not anchor valuation.
Relative strength. Lagging the group. The only one of the four down over 3 months (-4.8%) and the furthest from its high (-8.1%).
It only edged back above its 200-DMA ($219.75) today on the sector-wide gap, so the breakout is not established.
Valuation. Skyrizi/Rinvoq franchise is real and cash-generative (FCF yield 4.4%, 70% gross margin), but the balance sheet is the most levered in the group (net-debt/EBITDA 3.6x) with negative book equity from Humira-era buybacks/Allergan goodwill, and trailing P/E of 96x is distorted by IPR&D charges. Levered, not cheap.
Relative strength. LEADING XLV: YTD +14.8% vs XLV -2.2%; 3m +27.5% vs -3.2%; 1m +5.8% vs +5.0% (inline)
Valuation. Pristine net-cash balance sheet and a real GLP-1 mix tailwind, but a 40x P/E on mid-single-digit total revenue growth prices in continued acceleration.
Healthcare / pharma laggard-to-leader turn
emerging-early●●○medium✦ 822 names▾
What’s driving it. A real managed-care earnings turn, not just a chart bounce. UNH's Q1-2026 8-K confirms $111.7B revenue, an improving medical-cost ratio (83.9%), and FY26 adjusted-EPS guidance raised above $18.25.
XLV gapped above both its 50- and 200-day (+3.07% on the day) while still only -2% YTD and ~5% below its high, so there is room before it is extended.
Durability. Sustainable as a sector turn, but the whole basket gapped hard on June 4 so the timing is poor. The base is multi-week and the earnings recovery is confirmed forward, which distinguishes it from the financials reflex.
The caveat is that FY25 trailing financials still show the margin damage — the turn is a 2026 forward story not yet fully in the numbers.
Leaders’ fundamental health. Mixed and improving. The managed-care names (UNH, ELV) carry compressed margins right now — UNH net margin fell to 2.7% and ROIC to 8.2% in FY25, ELV similar at 2.8% net — but both are cheap (UNH 24.9x, ELV 13.7x P/E) with solid FCF yields (5.4% and 4.1%).
The thesis hangs on the FY26 margin recovery landing. ABBV is the most levered (3.6x).
In aggregate, depressed but recovering profitability at undemanding multiples — the value support is real if the margin turn holds.
Current leadersUNH · ELV
+ New leadersELVnew breakoutELV surged +4.64% to $409.44 and printed a brand-new 52-week high ($411.80 = day high), trading well above both its 50DMA ($351) and 200DMA ($336) — the cleanest fresh-high breakout in the group.UNHreturningUNH at $396.47 (+5.16% day) is a genuine laggard-to-leader return, sitting just 1.9% below its $404.15 52wk high and above both its 50-DMA ($344.51) and 200-DMA ($328.04) after recovering off its $234.6 year-low.
Relative strength. Leading. The genuine laggard-to-leader name.
Reclaimed both the 50-DMA ($344) and 200-DMA ($328) and now sits near its 52wk high, well ahead of the XLV proxy (only -5.3% from its high).
Valuation. Reasonable multiple for the sector at 24.9x P/E, but FY25 margins compressed hard (net 3.6%->2.7%, ROIC 12.3%->8.2%) and the thesis hangs on the FY26 margin recovery actually landing. Recovery confirmed in Q1 but not yet in trailing numbers.
Relative strength. Leading - the cleanest breakout in the group. At a brand-new 52wk high, well above the 50-DMA ($351) and 200-DMA ($336).
A more complete breakout than UNH, which is only just reclaiming its MAs.
Valuation. Cheapest of the four at 13.7x P/E and 0.39x sales - real valuation support if the margin thesis holds. But FY25 margins eroded (net 3.4%->2.8%, ROIC 6.7%->6.6%) and at a fresh high it has the least cushion if medical-cost-ratio reaccelerates.
Biotech laggard-to-leader (small/mid-cap)
emerging-early●●○medium▲ 46 +83 names▾
What’s driving it. An early-cycle laggard group turning, helped by AI-discovery demand and clinical catalysts. XBI is in a strong uptrend (+9.4% YTD).
June 4 was a broad biotech up-day (XBI +2.8%), so single-name strength reflects beta as much as idiosyncratic leadership.
Durability. Short-to-medium term and selective. This is the earliest, highest-beta slice of the healthcare turn.
SDGR is the genuine laggard-to-leader (+22.9% 1m / +20.7% 3m off a -43%-from-high base, reclaiming its 200-day). CRSP is a real but unconfirmed turn.
The move is only weeks old and the two RS leaders are clinical-binary, so leadership can fail at the 200-day. Durable only if the broader healthcare turn holds.
Leaders’ fundamental health. Weak where it leads, strong where it lags. The two RS leaders carry the theme but are fundamentally Weak: SDGR is pre-profit (negative operating margin, ROIC ~-30%, one lumpy year of positive FCF), and CRSP is clinical-binary (FY25 revenue collapsed to ~$3.5M, -$582M net loss, funded by a ~$2.44B cash pile after a $600M convert).
VRTX is the only Strong name (~$3.2B FCF, 18% ROIC, net cash) but its RS is weakest and it is mis-sized as a $112B large-cap for a small/mid theme. In aggregate, the entry call rests on the tape, not the income statement — size accordingly.
Current leadersSDGR · CRSP · VRTX
+ New leadersSDGRnew breakoutSDGR at $15.85 (+6.16% day) is the clearest laggard-to-leader turn, surging 27.4% above its 50-DMA ($12.44) and off its $10.95 year-low on a fresh relative-strength breakout, even while still 42.6% below its $27.63 52wk high.
− Removed leadersABVXstill strong droppedABVX was dropped on its prior broken-avoid/XBI-lagging read, but the live tape is firming not deteriorating — at $104.93 it jumped +16.39% on the day and reclaimed its 200-DMA ($109.69), so this is a not-re-surfaced biotech name showing renewed strength rather than a fresh deterioration signal.ALNYrs fadedALNY genuinely weakened — at $303.64 it sits 38.7% below its $495.55 52wk high and below both its 50-DMA ($307.82) and steeply-falling 200-DMA ($383.39), confirming the prior lagging read that its relative strength has faded despite a +3.78% bounce.MRNArotated outMRNA at $51.59 (+5.2% day) holds above its 50DMA ($49.88) and well above its 200DMA ($37.77) at 13.4% off its $59.55 high, so the name itself isn't broken — but the XBI biotech-laggard theme failed to confirm leadership, so it rotated out rather than personally weakened.
Relative strength. Leading on momentum — the clearest laggard-to-leader turn in the set. It crushes the XBI proxy over 1 month (+22.9% vs -0.1%) and 3 months (+20.7% vs +5.6%), trades well above its 50DMA ($12.44), and today is reclaiming its 200DMA ($16.05).
It is still negative YTD and -43% from its high, which is exactly the deep-hole base the theme targets.
Valuation. Small ($1.2B cap) and structurally unprofitable; FY2025 FCF turned barely positive (+$12M) but is lumpy on milestone/deferred-revenue timing. Software ACV growth has decelerated to the low teens, so the price-and-shovel thesis leans on AI-discovery demand staying intact and Bunsen monetizing.
Relative strength. Mixed, turning up. It beats XBI over 1 month (+6.3% vs -0.1%) and roughly matches it YTD (+8.7% vs +9.4%), but still trails over 3 months.
Today's +9.4% reclaimed the 50DMA ($51.84) and is pressing the 200DMA ($55.63) from below — a real turn attempt, not yet confirmed on a close above the 200DMA.
Valuation. Clinical-binary and pre-profit: FY2025 product revenue effectively went to zero and the company burned ~$346M of FCF. The ~$2.44B cash pile (cash plus marketable securities, post $600M convert) funds the pipeline for years, but the converts add dilution/leverage and value rests on the Casgevy ramp and unproven in-vivo CTX310.
Relative strength. Lagging the theme on trend. It is flat-to-down YTD (-2.6%) while the small/mid-cap biotech proxy XBI is +9.4%, and it trails XBI badly over 3 months (-7.6% vs +5.6%).
Today's +3.1% pop only lifted it a hair above its 50DMA/200DMA, which sit right on top of each other near $437.
Valuation. Best fundamentals in the cohort and the only profitable, cash-generative anchor, but the multiple is full. At EV/S ~9.5x and EV/FCF ~36x the price already discounts durable CF cash flows plus successful Journavx/Casgevy ramps.
Small-cap / equal-weight broadening
emerging-early●●●high✦ 853 names▾
What’s driving it. Genuine breadth, not a reflex. IWM is +11.6% over 3 months and closed effectively at a fresh high, +14.6% above its 200-day.
RSP equal-weight is also at a 52-week high. Unlike financials, the multi-week RS confirms the June 4 Russell-vs-flat-Nasdaq divergence is durable broadening.
Durability. Real but mid-stage — the easy early money is gone. This broke its base back in January and has been running since, so it is not a fresh breakout.
It is the best fresh non-tech add but a quality-screened proxy (CALF) is more durable than raw IWM at highs, since roughly 40% of the Russell is unprofitable.
Leaders’ fundamental health. Index-level, so judge it as a basket. The headline risk is composition: about 40% of the Russell 2000 is unprofitable, so raw IWM carries a large tail of low-quality, rate-sensitive names.
A free-cash-flow or quality screen (CALF) gives much healthier aggregate fundamentals than the raw index. Equal-weight RSP is structurally higher-quality than IWM.
Prefer the screened proxies.
Current leadersIWM · RSP · IJR
+ New leadersIJRnew breakoutIJR rose +1.31% to $140.26, within 0.2% of its 52-week high ($140.53) and above both its 50DMA ($133.54) and 200DMA ($124.99), confirming the small-cap broadening theme breaking to new highs.IWMnew breakoutIWM printed a fresh 52-week high at $292.01 (yearHigh $292.875, just -0.3% off), trading above its 50DMA ($272.66) and 200DMA ($254.85) and up +1.51% on the day, confirming a small-cap broadening breakout.RSPnew breakoutRSP closed at $210.83, essentially at a fresh 52-week high (yearHigh $210.945, -0.05% off), above its 50DMA ($200.96) and 200DMA ($194.87) and +0.76% on the day, confirming the equal-weight broadening breakout.
Relative strength. LEADING the broadening theme: IWM +18.6% YTD / +13.7% 3m vs cap-weighted SPY +11.0% YTD / +11.1% 3m — small-caps are +7.6pp ahead YTD, the clearest sign of a genuine breadth rotation. Trades well above its 50DMA ($272.66) and 200DMA ($254.85).
Valuation. As a broad small-cap index fund there is no firm-level valuation; the read is index posture — small-caps have re-rated hard off depressed multiples, and at a fresh 52-week high after a +18.6% YTD run the basket is extended near-term even as the structural broadening thesis stays intact.
Relative strength. Roughly IN-LINE-to-slightly-LAGGING the cap-weighted S&P YTD (RSP +10.1% vs SPY +11.0%) but LEADING on the trailing leg (+3.7% 1m / +5.1% 3m as the average stock catches up), so the equal-weight-vs-cap-weight broadening signal is improving. Above its 50DMA ($200.96) and 200DMA ($194.87).
Valuation. Equal-weighting tilts the basket toward cheaper mid-cap/value names that trade at a discount to the mega-cap-heavy SPX, so the fund itself screens cheaper than the cap-weighted index; just breaking to a new high on accelerating relative strength makes it a constructive add near the pivot rather than a chase.
Relative strength. LEADING the broadening theme: IJR +16.7% YTD / +9.9% 3m vs cap-weighted SPY +11.0% YTD / +11.1% 3m — small-caps +5.7pp ahead YTD. The softer +1.6% last month (vs SPY ~flat) shows it consolidating just under its high rather than rolling over.
Above its 50DMA ($133.54) and 200DMA ($124.99).
Valuation. The S&P 600's earnings-positive entry screen gives IJR a higher-quality, cheaper-on-earnings small-cap basket than IWM; after a strong YTD it is digesting gains in a tight range just below the high — constructive basing that keeps the broadening thesis intact without chasing.
Energy / oil & gas
extended-late●●○medium▼ 56 -134 names▾
What’s driving it. Year-to-date strength keeps it a real leader (XLE +31.4% YTD, second-best broad sector), but the near-term driver has stalled. XLE was -1.1% over 1m, only +4.6% over 3m, and a flat bystander to the June 4 broadening rather than a participant.
Durability. Mature and decelerating. It sits above its 200-day so the trend is not broken, but it is only +0.9% above its 50-day and -7.4% off its high — a leader at rest.
Downgraded from established to extended-late on the flattening multi-week RS. No fresh catalyst is pulling it higher right now.
Leaders’ fundamental health. Note: energy leader fundamentals were not independently verified in this run. The integrated majors (XOM, CVX) and large E&Ps generally carry strong balance sheets and high shareholder yields at this point in the cycle, but earnings are commodity-price-dependent and the group is cash-return rather than growth driven.
Treat as financially solid but cyclically mature.
Current leadersXOM · CVX · COP · EOG
+ New leadersCOPdisplaced incumbentCOP added at $119.23 (flat +0.15%) sits 12% below its 52-week high and just below the 50DMA ($122.49) but holds above the 200DMA ($104.11) in a rotating energy theme, so it earns a slot on relative resilience rather than a new breakout.CVXdisplaced incumbentCVX added at $188.35 (-0.72%) is 12% below its 52-week high and just under the 50DMA ($191.24) but above the 200DMA ($170.32), so it joins as a steadier energy proxy on the theme's rotation rather than on its own breakout.XOMdisplaced incumbentXOM at $152.09 (-0.29% day) is an energy-theme leadership name basing 13.8% below its $176.41 52wk high — fractionally under its 50-DMA ($154.31) but holding well above its rising 200-DMA ($132.58), a constructive trend rather than a fresh high.
− Removed leadersFANGstill strong droppedFANG at $202.94 is just 5.4% below its 52-wk high ($214.51) and remains above its 50-DMA ($196.56) and 200-DMA ($164.18); today's -3.63% pullback is intra-uptrend noise, so it is still strong and merely not re-picked.SLBstill strong droppedAt $58.01 it is just 1.4% off its 52-wk high ($58.82), above both its 50-DMA ($54.12) and 200-DMA ($43.82) and up +2.0% on the day — still strong on the tape, simply not re-surfaced this run, so this is not a deterioration signal.WMBrs fadedAt $72.43 it is 9.6% off its 52-wk high ($80.08) and below its 50-DMA ($73.63) though still above its 200-DMA ($65.81); the loss of the 50-DMA while energy peers (SLB near highs) lead confirms genuinely faded relative strength.
Relative strength. LAGGING its theme proxy XLE: YTD +26.4% vs XLE +31.4%, and 3m +1.5% vs XLE +4.6%. The megacap integrated trades with lower beta than the energy ETF and has trailed in the YTD rally.
Valuation. Highest-multiple of the integrateds (EV/EBITDA 8.2x) reflecting balance-sheet quality and downstream/chemicals diversification, but 2025 earnings fell with lower crude (EPS $6.66 vs $7.84). Premium is defensible on a fortress balance sheet but offers little margin of safety vs cheaper peers.
Relative strength. LAGGING its theme proxy XLE: YTD +23.6% vs XLE +31.4% (the weakest of the four names) and 3m +1.3% vs XLE +4.6%. Earnings compression and Hess-integration overhang have kept it behind the sector.
Valuation. 2025 earnings dropped sharply (EPS $6.65 vs $9.76), pushing the trailing P/E to ~23x and the dividend payout above 100% of earnings — covered by cash flow but not net income this cycle. Cheap on EV/EBITDA (7.8x) but the lowest ROE/ROIC and weakest current-year profitability of the group.
Relative strength. Modestly LAGGING its theme proxy XLE: YTD +27.4% vs XLE +31.4% and 3m +3.1% vs XLE +4.6%, though it is the only one of the four growing revenue. Recent 1m softness (-4.6%) is a pullback from the broader energy bid.
Valuation. Best growth-and-value combination of the four: the only name growing revenue (+7.5%, helped by Marathon) while trading at a low EV/EBITDA of 5.8x with a 14% FCF yield. Pure-play E&P scale at a clear discount to the integrateds, with a solid investment-grade balance sheet.
Relative strength. LEADING its theme proxy XLE: YTD +34.2% vs XLE +31.4%, and decisively on 3m at +10.2% vs XLE +4.6%. At only -7.2% from its 52-week high it sits closer to highs than the ETF (-7.4%) and is the relative-strength leader of the group.
Valuation. Highest-quality and highest-return E&P in the cohort: 50% EBITDA margins, ~17% ROE, lowest leverage (net debt/EBITDA 0.44x) and a net-cash-style balance sheet, yet the cheapest P/E (~11x) and lowest EV/EBITDA (5.5x). Low-cost Permian/Utica acreage justifies its leadership; revenue dipped only on price, not volume.
Defense / aerospace & drones
emerging-early●●○medium✦ 415 names▾
What’s driving it. A single sector-wide news event drove June 4: the Pentagon is weighing funding and equity support for domestic drone production, lifting the whole basket 12-14% intraday. This is a basket sympathy spike, not idiosyncratic relative strength.
The structural >$74B FY27 unmanned-systems budget is the real catalyst underneath.
Durability. Short-term burst on most names, durable only on GE. The hard RS tempers the narrative badly: ITA is +8.0% over 1m but -6.2% over 3m and -7.6% off its high — a recovery, not confirmed leadership.
Re-acceleration with room IF relative strength persists, but the June 4 pop is a headline bounce, not a re-rating. Needs follow-through to earn a leadership grade.
Leaders’ fundamental health. Wide spread, mostly poor at the leaders that move. GE Aerospace is the one Strong, genuinely-leading name: 47% ROE, FCF-positive, low leverage, above both moving averages near its high.
The rest are weak or broken: KTOS is a 606x P/E, 1.6% net margin, negative-FCF name down 53% from its high; AVAV has deteriorating margins (net 5.3%, down from 8.3%) and negative FCF; PLTR is operationally elite (36% net margin) but at 73x sales and down 31% YTD. In aggregate, GE is the only fundamentally and technically sound leader — the drone pure-plays are broken charts at extreme valuations.
Current leadersGE · RTX · AVAV · KTOS · PLTR
+ New leadersAVAVreturningAVAV jumped +6.75% to $204.40 and is back above its 50DMA ($185) but sits 51% below its 52-week high ($417.86) and well below the 200DMA ($262), so this is a recovery bounce/regain rather than a fresh-high breakout.GEnew breakoutGE rose +4.13% to $327.65, only 6% below its 52-week high ($348.48) and above both its 50DMA ($297) and 200DMA ($302), leading the defense/aerospace group on a constructive breakout from its base.KTOSbroken downtrendDespite an +8.5% pop to $63.40, KTOS remains -52.7% below its 52-week high ($134), still under its 50DMA ($64.40) and far below its 200DMA ($80.52), so the structure is broken-downtrend not leadership.PLTRbroken downtrendPLTR fell -0.35% to $141.70, sitting right on its 50DMA ($141.55), below its 200DMA ($161.35), and -31.7% from its 52-week high ($207.52), a broken-downtrend posture rather than leadership.RTXdisplaced incumbentRTX at $179.41 (+3.97% day) is constructively basing but not leading — it sits 16.4% below its $214.5 52wk high and just under both its 50-DMA ($184.06) and 200-DMA ($181.03), entering as a defense-theme fill rather than on a fresh breakout.
Relative strength. Leading. It is the only name in the group above both its 50DMA ($297) and 200DMA ($302) and within 6% of its high, beating the ITA proxy (+8.5% vs +6.7% YTD).
Valuation. Premium multiple near all-time highs. The engine-aftermarket annuity and high FCF justify a quality premium, but there is little torque to the specific drone catalyst.
Relative strength. Roughly in line, not leading. YTD ~matches the ITA proxy but it trails on 1m (+3.8% vs +7.5%) and 3m (-14.1% vs -6.2%), and it sits just below its 50DMA ($184).
Valuation. Reasonable for a diversified prime, but the counter-UAS line is a small revenue share so the drone narrative barely moves it; carries GTF engine charge and leverage risk.
Relative strength. Mixed. Strong 1m bounce (+22.5%) off a deep hole and back above its 50DMA ($185), but still negative YTD, below the proxy on 3m, far under its 200DMA ($262), and 51% off its high.
Valuation. Margins and returns compressed YoY and FCF is negative; the early-March price gap reflects the BlueHalo scale-up/dilution. 41x EV/EBITDA leaves no room for lumpy FMS timing or merger integration slippage.
Relative strength. Lagging badly. Despite the +8.5% pop, KTOS is down 16.5% YTD vs the proxy +6.7% and down 28.8% over 3m vs -6.2% — it sits below its 50DMA ($64.4) and far below its 200DMA ($80.5).
Valuation. A 606x P/E and 125x EV/EBITDA on 1.6% net margins and negative FCF — priced for a perfect unmanned ramp while the chart is broken. Today's spike is a budget-headline bounce, not a re-rating.
Relative strength. Lagging. The weakest YTD performer (-31% vs proxy +6.7%), sitting right at its 50DMA ($141.5) and well below its 200DMA ($161.3); RS has clearly rolled over relative to the hardware names.
Valuation. Operationally elite (36% net margin, ~48% revenue growth, FCF+), but at 73x sales / 225x EV/EBITDA the multiple is the risk — a budget-timing or growth-deceleration scare hits hardest, which is exactly what the -31% YTD reflects.
AI power generation / IPPs / uranium & nuclear
fading●●○medium▲ 58 +104 names▾
What’s driving it. The 'AI needs power' story has lost its tape. URA is -8.2% 1m / -4.7% 3m and below its 50-day.
CEG sits 18% below its 200-day, OKLO is -66% and SMR -79% off their highs. The whole proxy (NLR) is below both moving averages, so 'leadership' here means relative-strength survival within a correcting group.
Durability. Short-term broken; survivors are narrow. Only GE Vernova (best 3m/YTD RS, above 200-day), Talen and the fuel layer (Cameco) hold up, and even those have cooled — GEV is now below its 50-day and -10% on the month.
The speculative generation and SMR layer is the clear funding source. Not a place to add until the group reclaims trend.
Leaders’ fundamental health. Stretched-to-weak across the board. GEV is Stretched (~46x EV/EBITDA on ~9% growth, ~2% FCF yield, but net cash and a $163B backlog).
TLN is Weak — FY25 net loss, ROE -20%, net-debt/EBITDA 14.6x; leadership is a forward PPA-cash-flow story (Susquehanna/AWS through 2042), not realized earnings. CCJ is Stretched (~62x EV/EBITDA on 8.5% ROE).
BWXT is the best business (naval-reactor monopoly, 27% ROE) but the worst, broken chart. In aggregate, rich valuations resting on forward contract narratives, not current profitability.
Current leadersGEV · TLN · CCJ · BWXT
− Removed leadersCEGbroken downtrendCEG at $264.59 is 35.9% below its 52-wk high ($412.70) and trades below both its 50-DMA ($290.86) and 200-DMA ($322.37), down again today (-0.99%) — a broken downtrend in a power-for-AI theme that has lost leadership.OKLObroken downtrendAt $65.39 it sits 66.3% below its 52-wk high of $193.84 and below its 200-DMA ($85.72), only marginally above a falling 50-DMA ($63.09) — a genuinely broken downtrend, not a still-strong name.UECrotated outAt $14.14 it is 30.5% off its 52-wk high ($20.34) and pinned to its 50-DMA ($14.12) with only modest support from its 200-DMA ($13.87); paired with OKLO breaking down, the whole uranium/nuclear theme lost leadership rather than this name specifically collapsing.VSTbroken downtrendAt $153.70 it is 30.1% below its 52-wk high ($219.82) and now trades below both its 50-DMA ($154.41) and 200-DMA ($172.55), confirming genuine relative-strength deterioration in the power-for-AI IPP theme.
Relative strength. Leading. It is the strongest name in the complex on the 3-month and YTD tape, beating the nuclear/uranium proxy (NLR) by +24pp over 3 months and +41pp YTD.
Valuation. Rich and priced for perfection. EV/EBITDA is ~46x and FCF yield only ~2%, so an orders air-pocket would de-rate it fast.
Relative strength. Leading among the IPPs. It is the only name in the group holding above both its 50-day ($353) and 200-day ($372), and it has the best 1-month relative strength, beating the proxy by about 7pp.
Valuation. Leadership is contract-narrative, not current earnings. FY25 posted a net loss (ROE -20%) and net-debt/EBITDA is 14.6x; the bull case rests on the future PPA cash-flow ramp, not today's P&L.
Relative strength. Leading the fuel layer on a relative basis. It is up 24.6% YTD versus the proxy's +6%, and although it is down 5.2% over 3 months, that still beats the proxy's -9.6%.
It holds above its rising 200-day but sits right on its 50-day.
Valuation. Very rich for a miner and highly geared to uranium spot. EV/EBITDA is ~62x on single-digit ROE, so a pullback in spot from ~$86/lb would compress the multiple quickly.
Relative strength. Lagging / broken on the live tape. It is the only one of the four trading below BOTH its 50-day ($212) and 200-day ($195), it is down 12% over the past month, and it lagged the proxy on the 1-month read.
The +3.3% bounce on the day is off a broken structure, not a leadership base.
Valuation. Best business of the four (monopoly naval/government backlog, 27% ROE) but the worst chart. EV/EBITDA ~31x while price sits below both key moving averages — the tape, not the fundamentals, is the problem here.
Gold & precious metals
fading●●○medium▲ 50 +44 names▾
What’s driving it. There is no active driver right now. GDX is essentially flat everywhere (+0.9% 1m, +0.8% 3m, +0.7% YTD) and -26.3% below its 52-week high.
On the June 4 risk-on day gold rose only marginally and was NOT a rotation destination — it failed to act as a safe haven even when AI semis wobbled.
Durability. Digesting/fading, not leading. The narrative mistook a high absolute gold price for current relative strength.
The metal has held better than the miners, but neither is in an uptrend. Momentum has rolled over (GLD below its 50-day).
No reason to own it for relative strength here.
Leaders’ fundamental health. Note: precious-metals leader fundamentals were not independently verified in this run. The royalty/streaming names (FNV, WPM) typically carry high margins and clean balance sheets, while the miners (NEM, AEM) are more capital-intensive and cost-inflation exposed.
Regardless of fundamentals, the relative-strength read says this is a fading theme — do not own it for leadership.
Relative strength. LEADING its theme proxy GDX (VanEck Gold Miners ETF). YTD +8.5% vs GDX +0.7%, 3m -9.2% vs GDX -18.4%, and only -19.7% off its high vs GDX -26.3% off its high.
The world's largest gold miner is holding up better than the group through the spring pullback.
Valuation. Cheapest of the four on every multiple (~16.9x earnings, ~8.7x EBITDA) after a year of margin expansion lifted EPS from $2.86 to $6.41 and gross margin to 50%; net-cash balance sheet and 12% ROIC make this the value/quality anchor of the gold complex.
Relative strength. LAGGING its theme proxy GDX. Its 3m return of -24.0% is worse than GDX -18.4%, and at -30.7% off its 52w high it is more damaged than GDX -26.3%; YTD +4.3% trails GDX-relative peers NEM (+8.5%), WPM (+9.3%) and FNV (+13.9%).
Below both its 50-day ($194) and 200-day ($183).
Valuation. Operationally elite (58% gross margin, EPS doubled $3.79 to $8.86, virtually debt-free) but the priciest senior miner at ~20x earnings / ~10x EBITDA, so the sharp -31% drawdown from highs is a multiple/momentum reset rather than a fundamental crack; needs a confirmed turn before it is buyable.
Relative strength. LEADING its theme proxy GDX. YTD +9.3% vs GDX +0.7%, 1m -4.6% vs GDX -6.4%, 3m -16.6% vs GDX -18.4%, and -22.5% off high vs GDX -26.3%.
The streaming model holds margin better than the miners in a gold pullback.
Valuation. Streaming economics justify the premium: 72% gross / 82% EBITDA margins, EPS up $1.17 to $3.29 on +83% revenue, and a debt-free balance sheet, but at ~39x earnings and ~30x EBITDA the valuation prices in continued gold strength and the low FCF yield reflects upfront stream deposits.
Relative strength. LEADING its theme proxy GDX, and the strongest of the four. YTD +13.9% vs GDX +0.7%, 1m +0.6% vs GDX -6.4%, 3m -10.0% vs GDX -18.4%, and only -17.4% off its high vs GDX -26.3%.
The royalty model is the clear relative-strength leader of the precious-metals theme.
Valuation. Best balance-sheet and margin profile in the group (95% EBITDA margin, near-zero capex, fully debt-free) with EPS up $2.87 to $5.86 as Cobre Panama overhang eased; the ~40x P/E and ~26x EBITDA are royalty-model premiums, but the 3.7% FCF yield and pristine balance sheet make the rich multiple defensible.
Financials / banks
fading●○○low✦ 414 names▾
What’s driving it. There is no multi-week driver — just one green candle on a deep laggard. XLF is up only 1.3% over THREE months despite the +2.6% session, is -4.7% YTD, and sits below its 200-day (52.19 vs 52.57).
The narrative read mechanical catch-up as a laggard-to-leader inflection; the tape says it is not yet there.
Durability. Not confirmed. This is the headline contradiction the data resolves against the narrative.
KRE (regional banks) is better — +8% YTD, above its 200-day — but still modest and -5.5% off its high. Financials need more than one week of follow-through above the 200-day before they earn a leadership grade.
Kept explicitly as a NOT-confirmed candidate.
Leaders’ fundamental health. Note: financials leader fundamentals were not independently verified in this run. Money-center banks (JPM, GS) are generally well-capitalized with strong returns at this point, but the sector's relative strength is the problem, not the balance sheets.
The point of flagging this theme is that it does NOT lead — fundamentals are not the reason to wait, the absent relative strength is.
Current leadersJPM · GS · OWL · SOFI
+ New leadersGSnew breakoutGS jumped +4.96% to $1,092.61 and tagged a fresh 52-week high ($1,095.90 = day high), trading far above its 50DMA ($927) and 200DMA ($859) — a clean relative-strength new-high breakout for the financials theme.JPMnew breakoutJPM surged +3.34% to $310.89, reclaiming both its 50DMA ($303.49) and 200DMA ($305.89) and sitting only -7.8% from its 52-week high ($337.25), a financials leadership move back into uptrend.OWLreturningOWL jumped +5.16% to $10.19, regaining its 50DMA ($9.52) but remaining -51.7% off its 52-week high ($21.08) and far below its 200DMA ($13.64), so it is returning on a financials bounce, not on fresh strength.SOFInew breakoutSOFI at $17.15 (+2.82% day) is reclaiming its 50-DMA ($16.75) on heavy 61M volume in a fresh base-recovery move, though it remains 47.6% below its $32.73 52wk high and well under its 200-DMA ($23.12).
Relative strength. Roughly in-line to slightly LEADING its theme proxy XLF: 3m +5.9% vs XLF +1.8% (lead) and YTD -3.5% vs XLF -4.7% (lead), though 1m +0.5% vs XLF +1.2% is a slight lag. Sits right at its rising 50/200-DMA (~$303-306) after a +3.3% session.
Valuation. Cheapest of the four at ~15.5x with a 15.7% ROE and a fortress balance sheet; record earnings power but the multiple already prices in best-in-class execution, leaving limited re-rating upside.
Relative strength. Decisively LEADING the theme proxy XLF on every horizon: 3m +30.8% vs XLF +1.8%, YTD +24.3% vs XLF -4.7%, 1m +18.9% vs XLF +1.2%. Trading essentially at a fresh 52-week high.
Valuation. Strong earnings inflection (net income +20%, EPS +24%) on a capital-markets recovery, but at a 52w high and 21x with a high-beta, cyclical revenue base the entry is extended and chasing rather than at support.
Relative strength. Sharply LAGGING the theme proxy XLF: YTD -31.8% vs XLF -4.7%, 3m -2.3% vs XLF +1.8%, 1m -5.2% vs XLF +1.2%. Trades well below its 200-DMA (~$13.64), roughly halved from its high.
Valuation. Fast-growing alternative-asset manager but GAAP earnings are thin and stock-comp/intangible-heavy, leaving a ~85x trailing P/E and a dividend that exceeds GAAP net income; the broken, halved chart reflects a market repricing the quality of those earnings.
Relative strength. LAGGING the theme proxy XLF over the meaningful horizons: YTD -34.5% vs XLF -4.7% and 3m -10.9% vs XLF +1.8%; only the 1m +7.0% vs XLF +1.2% bounce leads. Still below its 200-DMA (~$23.12) though back above the 50-DMA (~$16.75).
Valuation. High-growth, newly GAAP-profitable fintech bank, but at ~44x earnings and ~36x EV/EBITDA the valuation is rich against a still-modest 4.6% ROE and cash-consuming lending model; growth quality is improving but the multiple leaves little margin for error.
Software (SaaS / application)
fading●○○low✦ 342 names▾
What’s driving it. The AI-capex trade has not lifted software. IGV is -5.5% over 3m, -15.2% below its 52-week high (deepest of any tech proxy), below its 200-day, and red on the broadening day.
This confirms AI leadership is hardware and compute, not application software.
Durability. Fading. The important nuance the 'Tech +32% YTD' headline masks is that the tech leadership is narrower than it looks.
Software is a place the AI-capex dollars are NOT flowing right now. Not a place to add.
Surfaced only to keep the tech read honest.
Leaders’ fundamental health. Note: software leader fundamentals were not independently verified in this run. Mega-cap SaaS like MSFT carries elite margins and cash generation, but the theme-level relative strength is poor and that is the operative signal.
The businesses are healthy; the group is simply not where leadership lives.
Current leadersMSFT · CRM
+ New leadersCRMreturningCRM at $188.75 (-0.98% on the day) is 32% below its 52-week high ($276.80) and far under its 200DMA ($220.71), only just reclaiming the 50DMA ($181.12), so its inclusion is a laggard attempting to turn rather than relative-strength leadership.MSFTreturningMSFT at $428.05 has recovered above its 50DMA ($406.33) but is still -22.9% from its 52-week high ($555.45) and below its 200DMA ($457.29), so it is returning to relative strength off the lows rather than at new highs.
Relative strength. LAGGING its Software theme proxy IGV. Over 3m MSFT is +4.2% vs IGV +14.2%; over 1m +4.1% vs IGV +13.3%; YTD -11.5% vs IGV -5.4%.
The mega-cap has badly trailed the software complex's recovery off the spring lows.
Valuation. Premium but defensible: 31x earnings / 23.6x EBITDA for a 37% net-margin, 30% ROE compounder with fortress balance sheet; the ~23% drawdown from highs has compressed the multiple toward the more reasonable end of its historical range without impairing quality.
Relative strength. LAGGING its Software theme proxy IGV severely. Over 3m CRM is -6.3% vs IGV +14.2%; over 1m +0.9% vs IGV +13.3%; YTD -28.7% vs IGV -5.4%.
It is the worst-performing software name here and has not participated in the group's rebound.
Valuation. Cheapest of the cohort at ~24x earnings / 16x EBITDA with a 7% FCF yield, but the discount reflects decelerating ~10% growth and modest mid-teens ROE; quality is solid yet the deep, below-200-day downtrend makes it value-trap-prone until price stabilizes.
Fintech / stablecoins / crypto equities
fading●●○medium● 28 +13 names▾
What’s driving it. Capital is leaving, not entering. COIN trades 33% below its 200-day and 63% off its year high; CRCL is 70% off its high, round-tripping its entire 2025 re-rating.
On June 4, a risk-ON broadening day, the crypto complex was SOFT (IBIT -2.6%, IREN -5.5%), confirming it as a funding source rather than a rotation destination.
Durability. Fading, with a split. Fintech and crypto-beta have diverged — HOOD (+6.6%, a diversified broker) bounced while pure crypto-exchange names stayed weak.
The crypto-exchange and stablecoin proxies are broken; only diversified fintech is holding. Not a place to add crypto-beta.
Leaders’ fundamental health. Note: fintech leader fundamentals were not independently verified in this run. COIN and CRCL earnings are highly leveraged to crypto trading volumes and stablecoin float, so profitability is volatile and regime-dependent.
HOOD is the more diversified, more durable franchise. The relative-strength read (funding source) is the operative signal regardless.
Relative strength. LEADING its Fintech/crypto-equity theme proxy BITQ on the short term. Over 1m HOOD is +14.6% vs BITQ +4.6% (and jumped +6.6% on 6/4); over 3m +9.6% vs BITQ +33.0% it lags the broader basket, but it is the strongest of the two crypto-equity names here and is reclaiming its 50-day ($77.7).
Valuation. Richly valued at ~43x earnings / 25x sales, but uniquely backed by 52% revenue growth and a 42% net margin, so the multiple is growth-justified rather than purely speculative; the 25x EV/sales leaves no room for a growth stumble.
Relative strength. LAGGING its Fintech/crypto-equity theme proxy BITQ dramatically. Over 3m COIN is -20.2% vs BITQ +33.0%; over 1m -17.0% vs BITQ +4.6%; YTD -27.4% vs BITQ +37.8%.
COIN is in a deep independent downtrend while the crypto-equity basket rallied.
Valuation. Net income fell sharply YoY (FY25 $1.26B vs FY24 $2.59B) on only single-digit revenue growth, so ~37x earnings / 31x EBITDA prices in a crypto-cycle rebound that price action is not yet confirming; strong cash position cushions but does not justify the multiple at -63% from highs in a falling-knife trend.
Relative strength. MIXED vs theme proxy ARKF (ARK Fintech/Blockchain ETF): LAGGING on 1m (-24.3% vs ARKF -6.0%) and 3m (-13.9% vs -3.0%), but LEADING YTD (+8.5% vs ARKF -16.1%). The post-IPO blow-off has unwound far harder than the broader fintech/crypto-equity complex.
Valuation. Real and fast-growing stablecoin franchise (USDC) now GAAP-profitable on a quarterly run-rate, but structurally thin gross margin (most reserve yield flows to distribution partners) and full interest-rate sensitivity make ~9x sales a demanding multiple. Quality is improving (last 3 quarters profitable, fortress balance sheet) but the model's earnings power is rate-dependent.
Quantum Computing
fading●○○low● 45 -24 names▾
What’s driving it. No fundamental driver — this is pure narrative and positioning. IONQ is -3.8% and 22% off its year high; RGTI is below its 200-day and 58% off its high.
Both fell or stalled while non-AI cyclicals rallied on June 4 — the behavior of a crowded cohort that gets de-grossed when risk appetite narrows.
Durability. Fading. Downgraded from extended to fading because it sold off into a risk-on tape, which is the worst tell.
Pre-revenue and headline-driven. Not a leadership group — a speculative cohort to avoid until it stops underperforming on up days.
Leaders’ fundamental health. Weak and pre-revenue. IONQ carries a ~$24.5B market cap on minimal sales.
These are pre-commercial, cash-burning companies whose valuations rest entirely on a distant technology narrative, not on margins, growth or balance-sheet strength in any conventional sense. Treat as venture-stage equity in public clothing.
Relative strength. LEADING the theme proxy QTUM (Defiance Quantum ETF): 3m +76.9% vs QTUM +46.3% and 1m +43.5% vs +22.7%; roughly in-line YTD (+40.3% vs +48.2%). The largest-cap pure-play and the clear quantum momentum leader on a 1-3m basis.
Valuation. Best top-line growth and balance sheet among the trapped-ion/quantum pure-plays (rev tripled, ~$1B war chest), but deeply unprofitable with a triple-digit EV/sales multiple that prices years of execution. A momentum vehicle, not a value or quality name.
Relative strength. LAGGING the theme proxy QTUM badly YTD (+2.3% vs QTUM +48.2%) and slightly trailing on 3m (+37.1% vs +46.3%); only the recent 1m bounce (+36.5% vs +22.7%) is ahead. The weakest of the three quantum pure-plays on a YTD basis.
Valuation. Worst fundamentals of the cohort: revenue actually shrank YoY to a token $7M against an $8B market cap (~1000x sales) with negative gross margin. Down 58% from its high, below recovering 200-day, and lagging its own theme — a broken, story-driven name with no fundamental support.
Relative strength. IN-LINE with the theme proxy QTUM on 3m (+46.1% vs +46.3%) and ahead on 1m (+32.0% vs +22.7%), but LAGGING YTD (-1.7% vs QTUM +48.2%) — a full round-trip on the year despite the strong recent bounce.
Valuation. Best revenue growth (+179%) and gross margin (83%) among the quantum trio with a well-funded balance sheet, but still deeply loss-making at ~300x+ sales. Chart has round-tripped to flat YTD and sits 41% below its high while bouncing above its moving averages — recovering but not yet confirmed.
Relative strength. LAGGING its quantum theme proxy (Defiance Quantum ETF, QTUM). QTUM is +51.8% YTD and +48.9% over 3m vs IBM's +1.9% YTD and +17.6% over 3m.
IBM is a $284B mainframe/consulting/software megacap where quantum is a small optionality slice, so it badly trails the pure-play quantum basket; even IBM's strong +31.7% trailing-month bounce only outpaced QTUM's +19.6% because IBM was rebounding off a deep ~$229 trough.
Valuation. At ~26x earnings and ~19x EV/EBITDA IBM is fully valued for a high-single-digit grower; the cash generation (~$12.4B FCF), 60% gross margin and 32% ROE are strong, but a levered balance sheet (3.1x net debt/EBITDA, sub-1.0 current ratio) and reliance on consulting/software rather than quantum economics make it a quality-but-not-cheap name with no near-term quantum earnings driver.
AI memory / HBM super-cycle
carried forward
established-leading●●●high▼ 91 -64 names▾
What’s driving it. A genuine DRAM/HBM shortage. Micron is verified at $1,079.57, up 1.45% and GREEN at its 52-week high ($1,088.89), trading ~3.1x its 200-day ($348).
Holding green while NVDA, PLTR and AMZN sold off is the tell that leadership is rotating into the memory bottleneck (MU +141% YTD, SanDisk +156% per web).
Durability. Short-to-medium term. Memory is historically boom-bust cyclical.
The 140-300% moves carry late-cycle risk if DRAM pricing rolls over. This is the highest-conviction CURRENT-momentum theme, but it is established-leading, not emerging — the easy money is behind it.
Leaders’ fundamental health. Improving sharply but cyclical. Micron's revenue is inflecting hard on pricing, margins are expanding off the trough.
Balance sheets are adequate. The whole group is geared to one variable — DRAM spot pricing — so fundamental health is only as durable as the shortage.
Relative strength. Mixed vs proxy SMH — LEADING YTD +81.8% vs SMH +68.1% (+13.7pp) and 1m +30.1% vs SMH +23.8% (+6.2pp), but LAGGING on 3m +50.9% vs SMH +57.3% (-6.4pp). Net at new highs with SMH
Valuation. Best-in-class WFE franchise: ~49% gross margin, 54% ROE, net cash and ~$4.9B FCF on +24% revenue growth. But at ~83x earnings and ~67x EV/EBITDA the stock has fully repriced the HBM/3D-NAND super-cycle into the multiple, leaving little margin for any capex air-pocket.
Relative strength. LEADING SMH on all horizons: YTD +215.8% vs SMH +68.1%; 3m +148.4% vs +57.3%; 1m +72.8% vs +23.8%
Valuation. Operationally inflecting hard (gross margin 40% and net income up ~11x YoY in FY25 on HBM), but the ~9x price re-rate since fiscal year-end pushes trailing P/E to ~140x and current EV/sales to ~33x. The thesis is entirely forward HBM earnings power; trailing multiples are stretched and FCF is still thin against heavy capex.
Relative strength. LEADING SMH massively: YTD +539.3% vs SMH +68.1%; 3m +194.2% vs +57.3%; 1m +40.1% vs +23.8%
Valuation. Trailing fundamentals are unprofitable (FY25 net loss -$1.64B, negative EBITDA/ROE/ROIC), so the ~40x re-rate of market cap is a pure forward-cycle bet on NAND pricing recovery. Balance sheet is sound (net cash, 3.6x current ratio), but at +672% YTD with no current earnings the stock is priced for a flawless memory up-cycle.
Relative strength. MIXED vs SMH: YTD +96.1% vs SMH +68.1% (leading); 3m +33.3% vs +57.3% (lagging); 1m +20.6% vs +23.8% (~inline)
Valuation. High-quality, asset-light tester: 59% gross margin, low-20s ROE, near-zero net debt. But only ~13% revenue growth and a high-60s/low-80s EV/EBITDA at ~118x earnings make the valuation the most stretched of the four relative to its growth, pricing in a sharp HBM-test acceleration that has yet to show up in the top line.
Selective medtech / device breakouts
carried forward
emerging-early●○○low▲ 54 +123 names▾
What’s driving it. Stock-specific structural growth catalysts. Edwards is just below its 52-week high after a clean six-month base breakout, with Q1-2026 heart-therapy growth ~+42% YoY and raised FY guidance.
Glaukos is reclaiming its 200-day from below. The selectivity is the signal: ISRG is explicitly excluded as a falling knife at its 52-week low.
Durability. Short-term and fragile because it rests on 2-3 names. The broad device proxy IHI is the single weakest in the RS set (-25% off its high), so there is no sector tailwind underneath.
This is a stock-picker's theme, not a own-the-group theme.
Leaders’ fundamental health. The named breakouts (EW, BSX) are healthy — profitable, growing, reasonable balance sheets — but the proxy weakness signals the average device name is struggling. Lowest conviction in the set for exactly this reason: the health is concentrated in a handful of names, not the group.
Current leadersEW · GKOS · MDT
− Removed leadersBSXbroken downtrendBSX at $48.85 is 55.4% below its 52-wk high ($109.50), sits below both its 50-DMA ($58.78) and 200-DMA ($84.39), and is hovering near its 52-wk low ($47.17) — a genuinely broken downtrend.
Relative strength. LEADING proxy IHI strongly — YTD +2.5% vs IHI -19.4% (+21.9pp); 3m +2.6% vs IHI -15.2% (+17.8pp); 1m +4.9% vs IHI -0.1% (+5.0pp). EW grinds to new highs while the device-ETF is in a downtrend
Valuation. Premium structural-heart franchise valuation (P/E 46x, EV/EBITDA 33x) reflecting 78% gross margins, 11.5% revenue growth, ~$1.34B FCF and a net-cash balance sheet. The trailing P/E is flattered by FY24's discontinued-ops gain (Critical Care sale); on continuing EPS of $1.84 the multiple is rich but supported by durable TAVR/TMTT growth — a high-quality compounder priced for it.
Relative strength. LEADING its proxy IHI (iShares US Medical Devices ETF) on 3m/YTD: GKOS YTD +7.8% vs IHI -19.8% (49.87 vs 62.15); GKOS 3m +5.4% vs IHI -15.2% (49.87 vs 58.80). It LAGGED the proxy over 1m: GKOS -10.4% vs IHI -0.1% (49.87 vs 49.92), giving back its May extension while the ETF stayed flat.
Net: clear sector leader on the medium/long lookbacks.
Valuation. Hyper-growth, 77%-gross-margin ophthalmic-device story trading at ~13x EV/sales while still deeply GAAP-unprofitable and FCF-negative (R&D 30% of revenue). The premium multiple is justified only if the iDose/iStent ramp converts to operating leverage; net-cash balance sheet funds the burn for now.
Relative strength. Roughly TRACKING / slightly leading proxy IHI but both deeply negative. YTD MDT -14.7% vs IHI -19.8% (mild lead); 3m MDT -14.3% vs IHI -15.2% (in-line); 1m MDT +4.6% vs IHI -0.1% (leads on the bounce off its 73.31 year-low).
It is recovering with the proxy off the lows, not leading the theme higher.
Valuation. Large, durable cash machine — $36.4B revenue (+8.4%), $5.4B FCF, ~2.8% dividend — at a modest ~21x trailing earnings. Quality and income are solid, but ~8% top-line growth and a still-below-50dma/200dma chart mean the +5.7% earnings pop off year-lows is an unconfirmed turn rather than a reclaimed trend.
Neocloud / AI Datacenter Buildout (GPU-rental + servers)
carried forward
emerging-early●●○medium● 75 -33 names▾
What’s driving it. Vera Rubin NVL72 validation (CRWV, 06-01), HPE's record Q2 FY26 beat ($10.68B rev +40% YoY, biggest beat since 2018), and multi-year hyperscaler capacity contracts (NBIS Microsoft $17B + Meta $27B; CRWV $99.4B backlog; IREN Microsoft $9.7B + NVIDIA $3.4B).
Durability. Short-term momentum is real but fragile — three of four names carry Weak/Stretched balance sheets and the group is a laggard catching up to the extended parent (CRWV still ~33% below its $187 high). The contracts are multi-year, but the leverage (CRWV current ratio 0.31, working capital -$12.2B, Q1 FCF -$4.7B) means this is the highest tail-risk expression of the AI buildout; durability is contract-backed but financially precarious.
Leaders’ fundamental health. Weak-to-mixed in aggregate — the lowest-quality theme in the AI complex. CRWV is Weak (current ratio 0.31, WC -$12.2B, Q1 FCF -$4.7B, D/E 3.7x, EV/S ~27x).
NBIS is Stretched (EV/S ~68x, Q1 GAAP 'profit' is ~$743M non-operating other income masking a -$128M operating loss) but has the best balance sheet (current ratio 8.3x, near-net-cash). IREN is Weak (FCF -$0.92B/qtr, beta 4.18, revenue DECLINING sequentially $240M→$185M→$145M as the mining base winds down faster than AI ramps).
HPE is the only FCF-positive name (Mixed: EV/S ~5x, P/E ~16x, ~5.2% FCF yield) but thin AI-server margins.
Relative strength. LEADING proxy SMH hugely — YTD +122.2% vs SMH +68.1% (+54.1pp); 3m +149.4% vs SMH +57.3% (+92.1pp); 1m +87.0% vs SMH +23.8% (+63.1pp). Vertical move now -16% off high
Valuation. Far more reasonable valuation than the pure-plays (EV/S ~5x, P/E ~16x) and genuinely FCF-positive — the only one of the four generating free cash. But the stock doubled in a month (50DMA $28.63, price +64% above it; 200DMA $24.37, +93% above) and printed an all-time high on an earnings gap.
AI-server margins are thin/pass-through; legacy server/networking/Juniper dilute buildout purity. Lowest-risk fundamentally but most chase-extended technically.
Relative strength. LEADING proxy SKYY (First Trust Cloud Computing ETF) on every lookback: YTD IREN +63.7% vs SKYY +13.8% (147.99 vs 130.06); 3m IREN +41.4% vs SKYY +32.6% (147.99 vs 111.59); 1m IREN +25.0% vs SKYY +16.8% (147.99 vs 126.69). Far above its 50- and 200-day (49.21 / 46.39), but -5.5% on the day and -19.5% off its high = pulling back from an extended run.
Valuation. Highest-risk of the four: beta 4.18, an unfinished pivot from Bitcoin mining to AI cloud (revenue actually fell sequentially $240M Q1 -> $185M Q2 -> $145M Q3 FY26 as mining cash flows are abandoned), deeply FCF-negative (-$0.92B/qtr), and GPU-asset-backed leverage ($3.65B) that amplifies downside if AI-cloud ramp slips or GPU collateral values fall. Retrofit execution to contracted 480MW AI spec is unproven.
Sizing it as a leader overstates a still-transitioning, leverage-dependent story — the proposed high-beta-expression tag is the honest call.
Relative strength. LEADING proxy SKYY massively on every lookback: YTD NBIS +210.1% vs SKYY +13.8%; 3m NBIS +165.7% vs SKYY +32.6%; 1m NBIS +47.3% vs SKYY +16.8%. Only -6.9% off its 52w high and trading ~2.25x its 200-day (115.42), 1.55x its 50-day (167.47) - the strongest and most extended name in the set.
Valuation. Best balance sheet of the four (current ratio 8.3x, effectively net cash, FCF near breakeven) and explosive revenue growth, but valuation is the richest in the group at EV/Sales ~68x. Q1'26 'profit' ($621M net income / $2.40 EPS) is driven by ~$743M of non-operating other income — core operating income was -$128M, so do not read the GAAP profit as operational.
Move is momentum-loaded (~7.6x off its 52w low in a year); Netherlands/post-Yandex structure adds governance optics. The strongest tape but the most stretched multiple.
◆Core watchlist — the fundamentally-strong names we track
The persistent core. Leaders scored 0–100 (deterministically, from a point-in-time fundamentals cache) on a CANSLIM + SEPA growth-leader quality fingerprint — durable revenue growth, earnings inflection, margin expansion, high ROIC, and free-cash-flow generation (O’Neil + Minervini + the quality-factor literature), plus a small-cap runway tilt. Winner-grade names (≥60) are carried forward run-to-run and tracked here. The RS leaders that fail the profile still appear on the theme cards as current momentum, but are NOT tracked (momentum is transient). Quality measures “a great, improving business now”; the runway term is the one factor earned by our own survivorship-corrected backtest (among RS leaders, smaller cap was the only strong forward signal — a fat upside tail), gated on cash support so it rewards small cash-generative growers, not cash-burning lottery tickets. A high score on a mega-cap is still a quality read (its runway is capped), not a forward-multibagger one. Descriptive, not a forecast.
Entry. constructive-basing — at its 52-week high, above both moving averages, but a steady leader rather than a parabola, so a pullback toward the 50-day is a clean add
Thesis. The cleanest, highest-quality way to own AI-compute leadership. TSM gates the entire chain — leading-edge logic plus CoWoS packaging — and it actually led on the day the theme's other names wobbled.
It rose +1.9% on June 4 while AVGO fell 12.6%, which is real pick-and-shovel breadth, not a single crowded bet. This is the entry the original thesis got right: NVDA is the fundamental anchor but a relative-strength laggard, while TSM is the steady co-leader you can actually buy near a base.
Risk. Single-node geopolitical/Taiwan concentration is the binding tail risk for the whole AI-compute chain — that is the reason to own it, but also the one thing that breaks it. It also slightly lags the SMH proxy on 3m/YTD, so it is a quality co-leader, not the fastest mover.
Entry. buyable-near-pivot — steadiest name in the group, sits only 4% off its high above both moving averages, lowest near-term extension of the four
Thesis. The only buyable-near-pivot name in a leading theme where the other three are extended. The data-center buildout layer held its uptrend while the AI-power-generation trade broke, and ETN is the highest-quality, most reasonably-priced way to own it.
The trade-off is honest: its data-center exposure is diluted by slower vehicle, aerospace and industrial end-markets, so it moves less than the pure-plays. That is exactly why it is not extended when VRT, NVT and PWR are.
Risk. Lowest relative strength of the four (+28% YTD vs +63-84% for the pure-plays) — diversified end-markets mute the AI signal, so it leads on quality but lags on momentum. If the buildout theme broadly de-rates on a capex air-pocket, the whole group goes.
↗Healthcare / pharma laggard-to-leader turnextended-chasing on the da
Price $409.44 (2026-06-04). 1m +10.1% / 3m +40.4%, only -0.6% from its high. P/E 13.7x, EV/EBITDA 10.5x, net margin 2.8%, ROE 12.9%, ROIC 6.6%, FCF yield 4.1%, net-debt/EBITDA 2.5x. XLV proxy: +5% 1m, just reclaimed its 200-day.
Entry. extended-chasing on the day — gapped +4.6% to a fresh high on the June 4 sector move, so wait for a pullback toward the 50-day rather than chasing the gap
Thesis. The cleanest technical breakout in the early healthcare turn AND the cheapest name in it. ELV broke to a fresh 52-week high, sits well above both moving averages, and trades at just 13.7x earnings and 0.39x sales — real valuation support if the managed-care margin recovery lands.
It is a more complete breakout than UNH, which is only just reclaiming its averages. UNH is the stronger confirmed fundamental turn (Q1 8-K showed an improving medical-cost ratio and a raised FY26 guide above $18.25), so own ELV for the chart and UNH for the earnings story.
Risk. Same sector-wide Medicare Advantage rate and Medicaid-redetermination cost-trend risk that broke the group in 2024-25 — a fresh medical-cost-ratio spike compresses the exact margins the thesis is built on. FY25 financials still show margin erosion (net 2.8%), so the recovery is forward-dated, not yet in trailing results.
Entry. constructive-basing — above both 50-day ($297) and 200-day ($302), within 6% of its high; a premium multiple near all-time highs, so add on weakness
Thesis. The only name in the defense/drone group that actually leads on the live tape, and the only sound way to play the FY27 unmanned-systems budget catalyst without buying a broken chart. The hard data inverts the proposed roles: KTOS and PLTR were mis-tagged as leaders but are down 53% and 31% from their highs below their 200-days, AVAV is a deep-drawdown reflex, and the whole basket's June 4 pop was a Pentagon-drone-funding headline, not idiosyncratic strength.
GE is above both moving averages, near its high, and beats the ITA proxy. The catch: little direct torque to the specific drone catalyst — you own it as the quality survivor, not the pure-play.
Risk. Premium multiple (38x P/E) near all-time highs with little direct exposure to the drone narrative that is driving the group's attention — the engine-aftermarket annuity justifies a quality premium but offers no catalyst torque. If the defense bounce fades (it is still -6.2% over 3m at the proxy level), GE holds up better than peers but does not run.
4Emerging / early-rotation watch
Small-cap / equal-weight broadening: the most credible non-tech RS inflection in the hard data
IWM +11.6% 3m to a fresh high, RSP equal-weight also at a 52-week high. TRIGGER to add: a pullback that holds the 50-day rather than chasing IWM at a fresh high, and prefer a quality/FCF-screened proxy (CALF) over raw IWM since ~40% of the Russell is unprofitable.
CONFIRMATION it is durable, not a one-day reflex: it is already accelerating on BOTH 1m and 3m, unlike financials.
Healthcare / managed-care turn: XLV just reclaimed its 200-day on a multi-week base, still only -2% YTD with room before extended.
TRIGGERthe whole basket gapped hard on June 4, so wait for a pullback toward the 50-day on UNH/ELV before adding rather than chasing the gap. CONFIRMATION: UNH's Q1 8-K (improving medical-cost ratio, raised FY26 guide) grounds the turn in earnings, not just price.
Biotech (small/mid-cap): XBI +5.6% 3m and only 4% off its high, with SDGR (+22.9% 1m) the genuine laggard-to-leader and CRSP a real but unconfirmed turn. TRIGGER for CRSP: a daily CLOSE above its 200-day ($55.63)
it is pressing it from below but not yet confirmed. Size small; both RS leaders are clinical-binary and pre-profit.
Defense / drones: ITA +8.0% 1m but still -6.2% over 3m and -7.6% off its high. TRIGGER to upgrade from emerging to leading: more than one week of follow-through above the 200-day on the group, and the single-name leaders (currently only GE) reclaiming their 200-days. The June 4 pop was a Pentagon-funding headline, not confirmed RS
do not buy the basket spike.
Financials (the explicit NOT-confirmed watch item): kept on the list precisely so the early-vs-reflex distinction stays honest. TRIGGER to take it seriously: XLF needs more than one week of follow-through ABOVE its 200-day (52.57).
Right now it is below it and only +1.3% over 3m. KRE (regional banks, +8% YTD, above its 200-day) is the better-positioned proxy if the rotation ever earns a leadership grade.
5Avoid / fading
Financials / banks: do NOT chase the June 4 +2.6% pop. XLF is up only 1.3% over THREE months, is -4.7% YTD, and is the ONLY major sector still below its 200-day. The 'Great Rotation into financials' fails the measured-return test
this is a deep laggard catching a one-day mean-reversion bid, not new leadership. The lone exception is GS: a fresh-52-week-high capital-markets leader (3m +30.8% vs XLF +1.8%, YTD +24.3% vs -4.7%) — own that name on its own merit, not the sector.
(It is extended here, so wait for an entry.)
AVGO (within the leading AI-semi theme): mislabeled 'dominant leader' but it is the GROUP LAGGARD on the live tape
down 12.6% on June 4, the only name below the SMH proxy on 1m, and -15.4% from its high. A name that just broke 12.6% at 68x P/E is broken-avoid near-term.
Let it reclaim its 50-day before trusting it.
MRVL (chasing risk, not a fade): the genuine RS leader (+318% 3m) but a parabola detached from earnings
Q1 FY27 net income was just $34.5M on $2.4B revenue, 1.4% net margin, ~29x EV/sales, beta 2.25. A June 2 'next trillion-dollar company' headline drove the final blow-off leg.
Leading, but NOT buyable — do not chase the melt-up.
AI power generation / IPPs / uranium & nuclear: a measurably broken momentum theme. URA -8.2% 1m below its 50-day, CEG 18% below its 200-day, OKLO -66% and SMR -79% off their highs.
The speculative generation and SMR layer is a funding source. Even the survivors have cooled (GEV now below its 50-day).
Not a place to add.
Gold & precious metals: retired from leadership. GDX is flat on every horizon (+0.9% 1m / +0.8% 3m / +0.7% YTD) and -26.3% from its high. Gold did NOT catch a safe-haven bid even when AI semis wobbled on June 4
the narrative mistook a high absolute price for current relative strength.
Crypto equities / bitcoin-beta: the clear funding source of 2026. COIN trades 33% below its 200-day and 63% off its high; CRCL is 70% off its high. On a risk-ON day (June 4) the complex was SOFT (IBIT -2.6%, IREN -5.5%). Only diversified fintech (HOOD +6.6%) is holding
avoid the crypto-exchange and stablecoin pure-plays.
Software (SaaS): a relative-strength laggard hiding inside tech. IGV is -5.5% over 3m, -15.2% from its high (deepest of any tech proxy), below its 200-day.
The AI-capex trade is NOT lifting software. Not a place to add.
Quantum computing: a crowded speculative cohort on probation. IONQ -3.8% and 22% off its high, RGTI 58% off its high below its 200-day
both fell or stalled while cyclicals rallied on June 4, the tell of a group that de-grosses when risk narrows. Pre-revenue and headline-driven (IONQ ~$24.5B mcap on minimal sales).
KTOS and PLTR (within the defense theme): both mis-tagged as leaders. KTOS is down 53% from its high below both moving averages at a 606x P/E with negative FCF; PLTR is the single WORST relative-strength name in the group, -31% YTD below its 200-day. Their June 4 pops were sector-sympathy on a budget headline, not company RS
do not buy them as leaders.
6Caveats
Data as of last close 2026-06-04. Everything here is a point-in-time relative-strength snapshot, not a forecast. Returns were computed against reference closes (1m ~May 4-5, 3m ~Mar 4, YTD ~Jan 2 or the 52-week range where a clean year-end anchor was not retrievable). Prices and fundamentals are from live FMP quotes, charts, statements and key metrics.
This is descriptive, not predictive. The readout describes which themes are leading RIGHT NOW on hard relative strength. It does not predict that they will continue to lead. Leadership rotates, and several of these themes (AI semis, copper, GLP-1) are explicitly flagged as extended/late-stage even while leading.
Rotation-reversal risk is live and acute. The whole healthcare and managed-care basket gapped hard on a SINGLE session (June 4). One green candle is not a trend — UNH/ELV/LLY are all within ~2% of their highs after that gap, so the entire basket is extended-chasing on this one day. The financials pop is the cautionary example: a one-day reflex the multi-week tape does not support.
Correlation hazard: many of these themes are the SAME underlying AI-capex bet wearing different clothes. AI semis, the data-center buildout layer, copper, and (formerly) AI power generation all rise and fall on hyperscaler capex. Owning all four is not diversification — it is one concentrated position. The buildout layer already proved this works both ways when it decoupled positively from the power-generation fade, but a genuine capex air-pocket would hit the whole cluster at once.
The original proposal's leader/laggard labels did NOT survive the live tape in several places, and those corrections are load-bearing. NVDA is the fundamental anchor but a relative-strength LAGGARD (it trails SMH on 1m/3m/YTD), not the 'single dominant leader.' AVGO is the group LAGGARD (-12.6% on the day), not a 'dominant leader.' In defense, only GE actually leads — KTOS and PLTR are broken charts mis-tagged as leaders. Trust the measured returns over the narrative wherever they disagree.
Two specific fundamental figures in the source theses were wrong and are corrected here: VRT's valuation is ~29x EV/EBITDA on FY25 (NOT the ~175x originally claimed — off by 3-6x), and NVT's leverage is 1.77x net-debt/EBITDA (NOT the ~5.8x claimed — overstated ~3x). The stocks are rich and NVT is acquisition-built, but the original red-flag magnitudes were hallucinated.
Fundamental health for several themes (copper, cybersecurity, energy, precious metals, financials, software, fintech) was NOT independently verified in this run — those leadersHealth notes are lighter-conviction descriptive reads, flagged as such. Treat the deeply-verified themes (AI semis, data-center buildout, healthcare/pharma, biotech, defense, nuclear) with higher confidence than the rest.
Remaining uncertainty I am NOT smoothing over: (1) the healthcare turn rests on a FY26 forward margin recovery that is confirmed in Q1 2026 guidance but NOT yet in trailing financials; (2) the two biotech RS leaders (SDGR, CRSP) are pre-profit and clinical-binary, so the entry rests on the tape, not earnings; (3) the small-cap broadening broke its base months ago, so it is mid-stage, not fresh; (4) financials and copper both had single-day moves (-1.3% copper, +2.6% financials) whose durability needs more sessions to confirm.
This is not personalized investment advice. It is a quantitative theme-leadership readout for a sophisticated reader who will do their own position-sizing, risk management and suitability assessment. Several leaders carry extreme valuations (LLY 47x P/E, PLTR 73x sales, KTOS 606x P/E) where the multiple, not the business, is the risk — size accordingly.
What’s driving it. Hyperscaler AI-compute capex is still ramping. The June 4 AVGO drop was a one-day de-risk of a crowded winner, not a theme break.
AVGO held its AI guide steady ($16B Q3) and its AI revenue still grew 143% YoY, while NVDA (+1.8%) and MRVL (+4.9%) rose the same session. Intra-group dispersion proves it was profit-taking, not a leadership failure.
Durability. Sustainable as a theme, but late-stage on price. The demand driver is multi-year and underwritten by named hyperscaler commitments.
The risk is not relative-strength failure, it is crowding and extension. So the theme leads but entries must be selective.
Quality (TSM) is buyable; momentum (MRVL) is a parabola you chase at your peril.
Leaders’ fundamental health. Bifurcated. The two best businesses (NVDA, TSM) are genuinely strong: NVDA runs 75% gross margins, 85% revenue growth, 63% ROIC, net cash, at a reasonable 33x P/E.
TSM is net cash, 66% gross margin, 32% ROE, ~20x earnings. But the two RS movers are weaker: MRVL is a 1.4% net margin, ~6% ROIC name at ~29x EV/sales, and AVGO is stretched at 68x P/E.
In aggregate the anchors are pristine; the momentum names are hollow.